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Summary
 
Adhesion of monocytes to the endothelium in lesion-prone areas is one of the earliest events in
fatty streak formation leading to atherogenesis. The molecular basis of increased monocyte ad-
hesion is not fully characterized. We have identified a novel vascular monocyte adhesion-asso-
ciated protein, VMAP-1, that plays a role in adhesion of monocytes to activated endothelium.
Originally selected for its ability to block binding of a mouse monocyte-like cell line
(WEHI78/24) to cytokine- or LPS-stimulated cultured mouse endothelial cells in vitro, anti-
VMAP-1 mAb LM151 cross-reacts with rabbit endothelium and blocks binding of human
monocytes to cultured rabbit aortic endothelial cells stimulated with minimally modified low
density lipoprotein, thought to be a physiologically relevant atherogenic stimulus. Most impor-
tantly, LM151 prevents adhesion of normal monocytes and monocytoid cells to intact aortic
endothelium from cholesterol-fed rabbits in an ex vivo assay. VMAP-1 is a 50-kD protein. Im-
munohistology of vessels reveals focal constitutive expression in aorta and other large vessels.
VMAP-1 is thus a novel vascular adhesion-associated protein that appears to play a critical role
in monocyte adhesion to aortic endothelial cells in atherogenesis in vivo.
 
A
 
dherence and accumulation of monocytes in discrete
 segments of arterial endothelium is among the earliest
detectable events in atherogenesis and is a central feature of
the pathogenesis of atherosclerosis (1). The recruitment of
monocytes from the blood is directed in vivo by selective
monocyte–endothelial cell recognition. This process sup-
ports regional immune responses by targeting cells to par-
ticular organs and tissues as a function of the local microen-
vironment and inflammatory state. Monocytes display a
number of potentially relevant adhesion molecules (2–4)
and endothelial cells overlying atherosclerotic lesions ex-
press a number of vascular ligands (5–7); however, the
identity of the molecules required for monocyte recruit-
ment associated with early lesion formation remains unclear
(6, 8, 9).
Cybulsky and Gimbrone (6) showed that the rabbit ho-
mologue of vascular cell adhesion molecule (VCAM)
 
1
 
-1 is
highly expressed in lesion areas. Monocytes express the
 
 
 
4
 
 
 
1 integrin receptor for VCAM-1, and VCAM-1 has
been shown to be upregulated focally in lesion-prone areas
of the rabbit aorta as early as 1 wk after initiation of an
atherogenic diet in rabbit (6). Indeed, in this model, upreg-
ulation of VCAM-1 precedes accumulation of monocytes
and macrophages (10) suggesting that expression of VCAM-1
may participate in initiation of diet-induced atherosclerosis
in rabbits. However, although antibodies to 
 
 
 
4 or VCAM-1
inhibit monocyte binding to activated aortic endothelial
cells in culture by 
 
 
 
50% in assays performed at 4
 
 
 
C, no
blocking by anti-
 
 
 
4 or VCAM-1 mAbs is observed when as-
says are performed at physiological temperatures (6). These
results suggest that while VCAM-1 may play a role in
monocyte accumulation in the cholesterol-fed rabbit model,
additional adhesion mechanisms must operate as well.
A potential requirement for multiple adhesion mecha-
nisms is not unexpected in light of current models of leu-
kocyte–endothelial interaction. Recruitment of lympho-
cytes from the blood has been separated into multiple
sequential steps characterized as contact initiation (“tether-
ing”), rolling, pertussis toxin-sensitive G
 
 
 
i-mediated acti-
vation, and activation-dependent integrin triggering and
arrest. Each step may be mediated by different adhesion or
 
1
 
Abbreviations used in this paper:
 
 GPI, glycosylphosphatidylinositol; HDL,
high density lipoprotein; HEV, high endothelial venules; ICAM, intracel-
lular adhesion molecule; MM-LDL, minimally modified LDL; PI-PLC,
phosphatidylinositol-specific phospholipase; MAdCAM, mucosal ad-
dressin cell adhesion molecule; PP, Peyer’s patch; RAEC, rabbit aortic
endothelial cells; RT, room temperature; VCAM, vascular cell adhesion
molecule; VMAP-1, vascular monocyte adhesion-associated protein 1.
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activation receptors, allowing specificity through use of
unique combinations of receptors to create specific homing
pathways (11–15). This model suggests that several adhe-
sion and activation pathways may work in concert to
achieve recruitment of monocytes into the vessel wall in vivo.
We have identified a 50-kD molecule participating in a
novel adhesion pathway involved in monocyte binding to
activated endothelium. Antibody blocking studies implicate
this novel molecule in monocyte adhesion in atherogenesis.
 
Materials and Methods
 
Cells and Reagents.
 
bEnd3 cells, a mouse EC line derived
from primary cultured mouse brain endothelial cells transformed
by polyoma virus middle T antigen (16; provided by W. Risau,
Max Plank Institute, Bad Neuheim, Germany), at passage 21–28
were maintained in cDMEM (DMEM [BioWhittaker, Inc.,
Walkersville, MD] supplemented with 5% fetal bovine serum
[endotoxin 
 
 
 
10 pg/ml; Gemini Scientific, Calabasas, CA] and 5%
Fetal Clone [endotoxin 
 
 
 
10 pg/ml; Hyclone Labs, Logan, UT]).
WEHI78/24 (mouse monocytoid) cells (17; gift of R. Coff-
man, DNAX, Palo Alto, CA) were grown in cDMEM and were
subcultured 72 h before the assay so that the cells reached a den-
sity of 1.8–2 
 
 
 
 10
 
6
 
 cells/ml within 12 h of the assay. U937 (hu-
man monocytoid) cells were grown in RPMI1640 containing 5%
fetal calf serum, 5% Fetal Clone, and 2 mM 
 
l
 
-glutamine (GIBCO
BRL, Gaithersburg, MD) and were used in log phase for binding
assays. In some experiments, WEHI78/24 cells were fluorescent
labeled by incubation in assay buffer (DMEM w/o sodium bicar-
bonate containing 20 mM Hepes, pH 7.0) containing tetramethyl
rhodamine isothiocyanate (2 
 
 
 
g/ml; Molecular Probes, Eugene,
OR) for 15 min at room temperature (RT). The cells were care-
fully layered over fetal bovine serum and centrifuged at 400 
 
g
 
 for
10 min to separate labeled cells from unincorporated dye. Cells
were washed in binding buffer and maintained at the subsequent
assay temperature.
Rabbit aortic endothelial cells (RAEC) were isolated and cul-
tured as described previously (18). Minimally modified low den-
sity lipoprotein (MM-LDL) was prepared by iron oxidation as
described previously (19).
Lymphocytes were isolated from peripheral and mesenteric
lymph nodes and neutrophils from bone marrow of 6–10-wk-old
BALB/c mice. Cells were used within 30 min of isolation.
 
Monocyte–Endothelial Binding Assay.
 
bEnd3 (mouse endothe-
lial) cells were passaged using a 1:3 split by growth area into 1-cm
 
2
 
wells of 8-well Lab-Tek
 

 
 chamber slides (Nunc Inc., Naperville,
IL) and allowed to grow to confluence for 2–3 d. Some wells were
treated with IL-1 (10 U/ml; R&D Sys., Inc., Minneapolis, MN),
TNF-
 
 
 
 (1 ng/ml), or LPS (1 
 
 
 
g/ml; 0111B12; Sigma Chemical
Co., St. Louis, MO) for 18 h, washed once with assay buffer, and
preincubated with 50 
 
 
 
l of 30 
 
 
 
g/ml blocking or negative con-
trol IgM
 
 
 
 mAbs (OZ42, LM5.9, LM137.3, and LM142.12) for
20 min at 4
 
 
 
C or RT. WEHI 78/24 or U937 (human monocy-
toid) cells (5 
 
 
 
 10
 
5
 
 for 4
 
 
 
C assays, 2 
 
 
 
 10
 
5
 
 for RT assays) were
added in 50 
 
 
 
l for a final volume of 100 
 
 
 
l. After a 30 min incu-
bation at 4
 
 
 
C or RT with continuous rocking to allow binding,
the top portion of the chambers and the gasket were removed
and the slide was dipped twice in Hepes-buffered saline to re-
move unbound cells and placed in 2% gluteraldehyde in PBS
containing 1 mM Ca
 
2
 
 
 
 and 1 mM Mg
 
2
 
 
 
. Slides were visualized
by light microscopy and the mean number of cells bound in 10
fields (representing 6.3 mm
 
2
 
) in triplicate wells was determined.
Studies of monocyte binding to RAEC were performed as
previously described (20). RAEC were either untreated or treated
for 4 h with MM-LDL before assay (20). In some cases, LM151,
or control IgM
 
 
 
 mAbs OZ42 or LM13.13 (each at 30 
 
 
 
g/ml)
were added to the endothelial cells for 20 min at 37
 
 
 
C before
adding freshly isolated human monocytes (20). LM13.13 recog-
nizes cultured RAEC by FACS
 

 
 (Becton Dickinson, San Jose, CA)
analysis and endothelium in frozen sections of rabbit aorta by im-
munofluorescence, and served as a binding antibody control.
 
mAb Production.
 
mAbs LM151, LM141, LM92, and LM13.13
were produced as follows. Fisher F344 rats (Charles River, Hol-
lister, CA) were immunized with TNF-
 
 
 
 stimulated bEnd3 (mouse
endothelial) cells. In brief, confluent cultures (350 cm
 
2
 
 surface
area) of bEnd3 cells were stimulated with TNF-
 
 
 
 for 18 h,
washed with copious volumes of HBSS to reduce serum protein
contamination, harvested with a rubber policeman, and injected
subcutaneously into a Fisher F344 rat. Rats received two subcuta-
neous boosts and a final intraperitoneal boost with identically pre-
pared antigen at 3-wk intervals. 3 d after the final boost, rats were
killed by CO
 
2
 
 asphyxiation, spleens removed aseptically, and hy-
bridomas prepared following standard fusion protocols using SP2/0
cells (American Type Culture Collection, Rockville, MD) as the
myeloma fusion partner. Hybridomas were plated in 24-well plates
resulting in formation of multiple independent clones (
 
 
 
50)
forming colonies in each well.
Hybridoma supernatants representing 
 
 
 
30,000 clones were
screened for their ability to stain bEnd3 cells by FACS
 

 
 analysis
and to block WEHI78/24 (mouse monocytoid) binding to bEnd3
(mouse endothelial) cells stimulated with LPS for 18 h. Wells
containing supernatants of interest were immediately subcloned
by limiting dilution and screened in the same assay. Isotypes were
determined by Ouchterlony double diffusion (ICN Biomedicals,
Inc., Costa Mesa, CA). mAbs were produced in serum-free me-
dium and isolated by serial ammonium sulfate precipitation (using
endotoxin-free media, buffers, and glassware) and are 
 
 
 
80% anti-
body. Control IgM
 
 
 
 mAbs LM5.9, LM137.2, and LM142.12, se-
lected for reactivity with bEnd3 cells by FACS
 

 
, were produced
in similar fusions using lysates of crude membrane preparations as
immunogen, and were isolated as above.
 
Biochemical Characterization.
 
Molecular weight determination
was performed by SDS-PAGE and Western blot analysis of re-
duced and nonreduced samples. In brief, untreated or cytokine-
treated confluent cultures of bEnd3 (mouse endothelial) cells or
untreated MM-LDL–treated confluent cultures of RAEC were
solubilized in 10% NP-40 (Boehringer Mannheim, Indianapolis,
IN) in 150 mM NaCl, 15 mM Tris, 1 mM CaCl
 
2
 
, 1 mM MgCl
 
2
 
containing 10 
 
 
 
g/ml aprotinin, 10 
 
 
 
g/ml leupeptin, 2 
 
 
 
 10
 
 
 
7
 
 M
pepstatin A, 1 mM PMSF, and 10 mM 
 
N
 
-ethylmalemide, pH
7.0. Lysates were ultracentrifuged at 100,000 
 
g
 
 for 45 min to re-
move insoluble material. Soluble material was diluted with SDS
sample buffer with or without 
 
 
 
-mercaptoethanol, separated by
SDS-PAGE, and electrotransferred to nitrocellulose membrane.
Blots were probed with control mAb MECA79 (IgM
 
 
 
; reference
21), LM151, LM141, or LM92 followed by alkaline phosphatase-
conjugated anti–rat IgM (Jackson ImmunoResearch Labs., West
Grove, PA) and developed using NBT-BCIP (GIBCO BRL) or
horseradish peroxidase–conjugated goat anti–rat IgM (Zymed
Labs., Inc., South San Francisco, CA) and visualized using the
chemiluminescence detection reagent ECL (Amersham, Arling-
ton Heights, IL).
Antigen was purified from detergent lysates of bEnd3 (mouse
endothelial) cells by affinity chromatography using LM151 co-
valently coupled to CNBr-activated Sepharose CL-4B (Pharma- 
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cia, Piscataway, NJ) at a concentration of 4 mg of IgM/ml of gel.
LM151-conjugated Sepharose was incubated overnight at 4
 
 
 
C
with lysates prepared as described above, washed with 0.65 M
NaCl, 10 mM Tris, and 10 mM phosphate, pH 7.4, and eluted
with 0.3 M NaCl containing 10 mM phosphate, pH 7.4, and
1.0% Empigen (Calbiochem Corp., La Jolla, CA). Purified mate-
rial was visualized by silver staining. Western blots of the peak
fraction were probed with LM151, LM141, LM92, and negative
control mAb MECA79 (IgM).
 
Immunohistochemistry, Immunofluorescence, and Flow Cytometry.
 
Frozen sections from multiple tissues from normal and TNF-
 
 
 
–
injected mice were prepared using standard avidin–biotin immuno-
histochemical protocols. Alternatively, mice were injected with 150
 
 
 
g of LM151 or control IgM mAb, killed after 10 min, perfused
with 20 ml of HBSS, and frozen section of tissues stained with
PE-conjugated mouse anti–rat IgG (Chomoprobe, Mountain
View, CA).
bEnd3 cells were grown to confluence, stimulated as described
and removed from flasks with 5 mM EDTA in HBSS. The cell
suspension was washed with cDMEM and incubated with LM151
(25 
 
 
 
g/ml) or MECA79 (negative control IgM; 25 
 
 
 
g/ml) fol-
lowed by PE-conjugated anti–rat IgM (Jackson ImmunoResearch
Labs.) and analyzed on a FACScan
 

 
.
BALB/c peripheral lymph node, spleen, Peyer’s patch (PP),
and bone marrow leukocytes were isolated and immunostained
with LM151, LM141, LM92, HECA452 (22), or MECA79 (neg-
ative control IgM
 
 
 
) followed by PE-conjugated anti–rat IgM
(Jackson ImmunoResearch Labs.) preincubated with purified mouse
IgG (to preadsorb anti–mouse cross-reactivity). Cells were ana-
lyzed on a FACScan
 

 
.
Although there are examples of glycosylphosphatidylinositol
(GPI)-anchored (23) proteins that are resistant to cleavage by
phosphatidylinositol-specific phospholipase C (PI-PLC) (23, 24),
the majority are sensitive; therefore, to determine if vascular mono-
cyte adhesion-associated protein-1 (VMAP-1) is a GPI-linked
protein, bEnd3 cells were pretreated with 500 
 
 
 
U/ml of PI-PLC
(from 
 
Bacillus cereus
 
; Sigma Chemical Co.) for 60 min at 37
 
 
 
C be-
fore immunostaining and FACS
 

 
 analysis. Mouse thymocytes
were treated in parallel and the cleavage of the GPI-linked pro-
tein Thy-1 was monitored as a positive control.
 
En Face Rabbit Aortic Endothelial–Monocyte Assay.
 
Male New
Zealand white rabbits were fed either normal rabbit chow or rab-
bit chow enriched with 1% cholesterol (ICN Biomedicals, Inc.,
Costa Mesa, CA). 1 d before they were killed (13 d after initia-
tion of diet), animals were lightly sedated with a 3-mg subcutane-
ous injection of acepromazine maleate solution (Ayerst Labs.,
Philadelphia, PA) and blood samples were collected in EDTA.
Total plasma cholesterol levels as well as high density lipoprotein
(HDL) were enzymatically measured (Sigma Chemical Co.). To-
tal cholesterol and HDL levels (mg/dl) of the control animals
were 53.8 
 
 
 
 11.1 and 28.7 
 
 
 
 3.7, respectively, whereas choles-
terol feeding for 2 wk resulted in 803 
 
 
 
 113 and 25.8 
 
 
 
 3.8 mg/
dl of total cholesterol and HDL, respectively.
2 wk after initiating the high cholesterol diet, rabbits were
killed by intravenous injection of sodium pentobarbitol (35 mg/kg;
Ayerst Labs.). Thoracic aortae were removed and placed in cold,
oxygenated phosphate-buffered saline, excess adventitial fat was
removed, and a 15-mm segment of thoracic aorta was excised im-
mediately distal to the left subclavian artery. Segments were opened
longitudinally and placed into 35-mm culture dishes previously
coated with a solid layer of 3% agarose and equilibrated with
binding buffer (HBSS supplemented with 2 mM Ca
 
2
 
 
 
, 2 mM
Mg
 
2
 
 
 
, and 20 mM Hepes, pH 7.0). The aortic segments were
pinned to the dish to expose the endothelial surface to the me-
dium and preincubated with LM151, control IgM mAb OZ42,
or binding control IgM LM13.13, each at 50 
 
 
 
g/ml, for 20 min
at RT. Culture dishes were then placed on a rocking platform
and 10
 
6
 
 tetramethyl rhodamine isothiocyanate–labeled WEHI78/24
cells were added, co-incubated for 30 min with constant rocking.
The dishes were rotated 120
 
 
 
 every 10 min to facilitate even
binding. After the co-incubation period, the medium was aspi-
rated and replaced with 2 ml of fresh binding buffer and allowed
to incubate with rocking for 5 min to remove unbound cells. The
washing procedure was repeated three times and then the aortic
segment was placed endothelial side up on a glass slide. Adherent
cells from at least 30 sites/segment were counted under epifluo-
rescent microscopy. The data are expressed as a percentage of the
number of adherent cells on LM151 treated versus control anti-
body-treated aortic segments.
 
Results
 
Anti–endothelial Cell Antibodies Inhibit Monocytoid Cell
Binding to Activated Endothelium.
 
WEHI 78/24 is a mouse
monocyte-like cell line (17) that expresses 
 
l
 
-selectin, 
 
 
 
4
integrin, LFA-1, and MAC-1 (25). It binds poorly to con-
fluent, unstimulated bEnd3 endothelial cells under the con-
ditions used here. After stimulation of bEnd3 cells for 4–20 h
with IL-1
 
 
 
 (10 U/ml), TNF-
 
 
 
 (1 ng/ml), or LPS (1 
 
 
 
g/
Figure 1. Anti–VMAP-1 mAbs block TNF- –induced WEHI78/24
(A) and U937 (B) binding to bEnd3 cells. bEnd3 cells were treated for 18 h
with TNF-  (1 ng/ml). Monolayers were preincubated with anti–
VMAP-1 mAbs LM151, LM141, and LM92, or with control mAb OZ42
(30  g/ml) for 20 min. WEHI78/24 (A), U937 (B), lymph node–derived
lymphocytes (C), or bone marrow-derived neutrophils (C) were added
and allowed to bind at RT (B; and A, right) or 4 C (all others) for 30 min.
The number of adherent cells in 10 fields in triplicate wells was deter-
mined in each experiment. n   4 for A and B; n   3 for C.2072 Vascular Molecule Involved in Monocyte Adhesion in Atherogenesis
ml), however, a dramatic increase in WEHI 78/24 cell bind-
ing is observed. mAbs were produced against 18 h TNF-
 –stimulated bEnd3 cells and screened initially for their ability
to block WEHI78/24 binding to TNF- –stimulated bEnd3
cells. Three inhibitory mAbs LM151, LM141, and LM92
(all IgM ) were isolated. All three blocked WEHI78/24 ad-
hesion to LPS (not shown) and TNF- –stimulated (Fig. 1
A) bEnd3 cells by  50% at both 4 C and at RT. They also
inhibited binding of the human monocyte-like cell line
U937, previously used to model involvement of “athero-
ELAMs” (6) in monocyte adhesion (Fig. 1 B). Mouse neutro-
phil and lymphocyte binding to LPS-stimulated bEnd3 cells
were not affected by mAbs LM151, LM141, and LM92
(Fig. 1 C). Binding of WEHI78/24 cells to TNF- –stimu-
lated bEnd3 cells was not influenced by the irrelevant
IgM  mAb OZ42 (Fig. 1 A) or by LM5.9, LM137.2, or
LM142.12, IgM  mAbs that stain bEnd3 cells with intensi-
ties greater or equal to LM151 by FACS analysis (not
shown).
Inhibitory mAbs Define a Common 50-kD Antigen, VMAP-1.
Western blots of NP-40 lysates of stimulated bEnd3 cells
were probed with the three blocking antibodies. Each rec-
ognized an identical pattern with a dominant species at 50
kD under reducing and nonreducing conditions (Fig. 2
A), indicating that the antigen does not exist as a disulfide-
linked dimer or multimer. Silver staining of LM151 affin-
ity-isolated material revealed a single band at 50 kD (Fig. 2
B). LM151, LM141, and LM92 (all IgM ), but not control
rat IgM  mAb MECA79, recognize LM151 affinity-iso-
lated material (Fig. 2 C) confirming that all three mAbs re-
act with the same 50 kD species, termed VMAP-1. The an-
tibody LM151 was selected for all subsequent studies.
To determine if VMAP-1 is GPI anchored (23), bEnd3
cells were treated with PI-PLC before immunostaining and
FACS analysis. PI-PLC failed to cleave VMAP-1 from the
surface of bEnd3 cells (not shown), indicating that VMAP-1
in not GPI anchored.
Expression of VMAP-1 on Arterial Endothelium In Vivo.
To ask if VMAP-1 were displayed by aortic and other large
vessel endothelium in vivo, frozen sections of heart, kid-
ney, lung, and lymphoid tissues were stained with LM151
or control IgM mAbs MECA79 or OZ42. As illustrated in
Fig. 3, anti–VMAP-1 mAb LM151 revealed focal staining
of the endothelial lining of valves in the aortic root (Fig. 3 A)
Figure 2. LM151, LM141, and LM92 all recognize an identical 50-kD
protein, VMAP-1, expressed by bEnd3 cells. (A) Western blots of deter-
gent lysates of TNF- –stimulated bEnd3 cells were probed with LM151,
LM141, LM92, or with control IgM MECA79 followed by horseradish
peroxidase–conjugated anti–rat IgM and visualized using enhanced chem-
iluminescence. Molecular mass markers (Mr   10 3) are indicated on the
left. LM151- or control IgM affinity-purified material was separated on
nonreduced SDS-PAGE and visualized by silver staining (B), or trans-
ferred to nitrocellulose and probed with LM151, LM141, LM92, or con-
trol IgM MECA79 and visualized as in A (C).
Figure 3. VMAP-1 is expressed by arterial and endocardial endothelial cells in vivo. Mouse heart section stained with anti–VMAP-1 mAb LM151 re-
veals intense reactivity (arrows) with endothelial cells covering valves in the aortic root (A), endocardium lining the ventricle (B), and endothelial cells in
a small artery (C). No staining was observed with a rat IgM control mAb (OZ42).2073 McEvoy et al.
and the heart ventricle (Fig. 3 B) as well as of subsets of ar-
teries and arterioles from many tissues including the heart
and kidney (Fig. 3 C). No reactivity was observed in capil-
lary endothelium or with postcapillary high endothelial
venules in peripheral lymph nodes or PP. VMAP-1 was
not restricted to vascular endothelium; LM151 also stained
subsets of bronchial and intestinal epithelial cells and stro-
mal elements in lymphoid tissues, but did not stain any leu-
kocytes (lymphocytes, monocytes, and neutrophils) isolated
from lymph nodes, spleen, or bone marrow, as assessed by
FACS analysis (not shown).
To confirm luminal display of VMAP-1, mice were in-
jected with LM151 or control IgM, killed, and perfused.
Frozen sections of tissues were stained by immunofluo-
rescence to detect retained antibody. Luminal, endothelial
VMAP-1 reactivity was observed focally in the thoracic
and abdominal aorta, heart ventricle, and in arterioles in
kidney, heart and other tissues (not shown).
Constitutive and LPS or Cytokine Upregulated Expression of
VMAP-1 by bEnd3 Cells. To assess the regulation of VMAP-1
in vitro, the relative amounts of VMAP-1 in lysates of un-
stimulated and LPS-stimulated bEnd3 cells were compared
by Western analysis (normalized to cell number). There
was significant superinduction of VMAP-1 after 24 h LPS
stimulation (Fig. 4 A). In addition, the surface expression of
LM151 by normal and stimulated bEnd3 cells was evalu-
ated by flow cytometry; LM151 is constitutively expressed
by bEnd3 cells and variable increases in expression are ob-
served after 4, 24, and 48 h of LPS stimulation (Fig. 4 B) as
well as IL-1  and TNF-  stimulation (data not shown). Re-
sults of a representative experiment illustrating superinduc-
tion of cell surface expression are shown in Fig. 4 B; how-
ever, the extent of superinduction assessed by flow cytometry
was variable, perhaps reflecting differences in endothelial
cell responsiveness or preinduction of VMAP-1 by the
conditions of culture.
LM151 Blocks Binding of Monocytes to MM-LDL–stimulated
Rabbit Aortic Endothelium In Vitro. The fat-fed New Zealand
white rabbit is a widely used animal model in atherosclero-
sis research. The three anti–VMAP-1 mAbs cross-react with
rabbit aortic endothelium as illustrated immunohistologic
staining with LM151 in Fig. 5 A. Furthermore, Western
blot analysis of RAEC indicate that anti–VMAP-1 mAb
LM151 recognizes a constitutively expressed 50-kD protein in
the rabbit (Fig. 5 B). The rabbit homologue of VMAP-1
can be superinduced in RAEC by MM-LDL stimulation, as
shown by Western analysis (Fig. 5 B) and flow cytometric
analysis (Fig. 5 C), which further reveals that increased ex-
pression after MM-LDL stimulation is due to an increase in
surface expression by all cells including a subpopulation of
RAEC with extremely high expression.
This fortuitous cross-reactivity with rabbit endothelium
allows the evaluation of the role of VMAP-1 in well char-
acterized in vitro assays relevant to atherogenesis. Berliner
et al. have previously shown that pretreatment of RAEC
with MM-LDL induces selective adhesiveness for mono-
cytes with no increase in neutrophil binding, for example
(26). Monocyte adhesion in this model does not involve
E-selectin, VCAM-1, or intracellular adhesion molecule
(ICAM)-1 (8). In contrast, incubation of MM-LDL–stimu-
lated RAEC with LM151 blocks binding of human mono-
cytes by  95% (Fig. 6). Irrelevant control IgM  mAb OZ42
and LM13.13 (an IgM -binding negative control mAb)
Figure 4. VMAP-1 is constitutively expressed by bEnd3 cells and can
be upregulated by LPS stimulation. Confluent cultures of bEnd3 cells
were left untreated or stimulated with LPS (1  g/ml) for 4- or 24-h and
the expression of VMAP-1 assessed by Western (A) and FACS analysis
(B). (A) Western blots of detergent lysates of an equal number of unstim-
ulated or 24-h LPS-stimulated bEnd3 cells were probed with LM151 or
control IgM mAb and visualized as in Fig. 3. (B) Relative fluorescence of
unstimulated, 4- and 24-h LPS-stimulated bEnd3 cells immunostained
with LM151 or control IgM (shaded histogram).
Figure 5. LM151 identifies a 50-kD protein expressed by rabbit aortic
endothelial cells. (A) LM151 immunofluorescence staining of a frozen
section of aorta from a cholesterol-fed rabbit. No staining was observed
with a rat IgM control mAb (MECA79). (B) Western analysis of deter-
gent lysates of unstimulated and MM-LDL (100  g/ml) stimulated RAEC
(normalized to cell number). Mr   10 3 indicated on the left confirms
same molecular mass as mouse protein and superinduction by MM-LDL.
(C) FACS analysis of unstimulated (U) and MM-LDL (100  g/ml)-
stimulated RAEC immunostained with control IgM (shaded histogram) or
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both failed to block monocyte binding to control or MM-
LDL–stimulated RAEC (Fig. 6). Thus, VMAP-1 plays an
important role in monocyte binding to MM-LDL–stimu-
lated endothelial cells, inhibiting an interaction that is inde-
pendent of known adhesion pathways.
Blockade of Binding to Cholesterol-fed Rabbit Aorta Ex Vivo.
To extend these in vitro observations to an assay system
better reflecting the complex nature of the prelesional ves-
sel, an ex vivo system was developed. The binding of
WEHI78/24 (mouse monocytoid) cells to intact aortic en-
dothelium from control or fat-fed rabbits was compared.
After 2 wk on a high cholesterol diet, a threefold increase
in monocytoid cell binding was observed (Fig. 7). Preincu-
bation of the aortic segments with LM151 dramatically in-
hibited WEHI78/24 binding, reducing adhesion nearly to
control levels (Fig. 7). LM13.13 (an IgM -binding nega-
tive control) failed to block WEHI78/24 binding to aortic
segments (n   2; data not shown).
Discussion
We have identified and characterized a novel vascular
molecule, VMAP-1, involved in monocyte adhesion to
stimulated mouse and rabbit aortic endothelium. Three in-
dependent mAbs against this molecule, LM151, LM141,
and LM92, block binding of WEHI78/24 mouse monocy-
toid cells (but not neutrophils or lymphocytes) to cytokine-
or LPS-stimulated mouse endothelial cells by  50% at
both 4 C and RT. Anti–VMAP-1 mAbs abrogate en-
hanced binding of monocytes to MM-LDL–stimulated
RAEC and cholesterol-enhanced binding to rabbit aortic
endothelium. The ability of anti-VMAP-1 mAbs to block
monocyte binding in these models of atherogenesis is
unique, as mAbs to other known adhesion pathways dis-
play little or no effect on monocyte or monocytoid cell
binding under conditions similar to those used here (RT or
37 C) to LPS-stimulated RAEC (6), to cytokine-stimulated
bEnd3 (mouse endothelial) cells (our unpublished observa-
tions), or to MM-LDL–stimulated RAEC (8). These data sug-
gest that VMAP-1 may play a critical role in monocyte ad-
hesion to vascular endothelium under pathophysiological
conditions such as hypercholesterolemia.
VMAP-1 is clearly distinct from known vascular adhe-
sion molecules VCAM-1 (110 kD), the GPI-linked variant
of VCAM-1 (VCAM-GPI; 47 kD), ICAM-1 (95 kD),
ICAM-2 (55 kD), mucosal addressin cell adhesion mole-
cule (MAdCAM)-1 (58–66 kD), E-selectin (115 kD), P-selec-
tin (140 kD), IG9 antigen (105 kD; reference 27), and
CD31 (platelet–endothelial cell adhesion molecule 1, 130
kD). First, the molecular weight (50 kD) distinguishes it
clearly from that of all but VCAM-GPI (28, 29), MAdCAM-1
(30), and ICAM-2 (31). Second, the expression pattern of
VMAP-1 in vivo (determined by immunohistochemistry
and immunofluorescence) is quite distinct from that of any
known adhesion molecule including MAdCAM-1 (21, 30)
and ICAM-2 (31). VMAP-1 is expressed by the endothe-
lium on a subset of arteries and arterioles, but is not detect-
able on capillary endothelium or high endothelial venules
(HEV) in peripheral lymph nodes or PP, whereas ICAM-2
is constitutively expressed by almost all endothelial cells, in-
cluding HEV in the human (32) and in the mouse (McEvoy,
L.M., and E.C. Butcher, unpublished observation), and vas-
cular MAdCAM-1 expression is highly and selectively ex-
pressed by HEV in PP and mesenteric lymph node. Third,
VCAM-GPI is GPI-linked (29), whereas VMAP-1 is not.
Fourth, ICAM-1 and -2 are expressed by lymphocytes and
leukocyte cell lines (31), whereas anti–VMAP-1 mAbs fail
Figure 6. LM151 blocks MM-LDL–induced binding of normal human
monocytes to RAEC. RAEC monolayers were incubated with MM-LDL
(100  g/ml) for 4 h and then preincubated with irrelevant isotype control
IgM  mAbs OZ42, RAEC-reactive IgM , control mAb LM-13.13, or
with LM151 (30  g/ml) for 20 min at 37 C. Human monocytes were
added to the cells and binding determined.
Figure 7. LM151 blocks binding of WEHI78/24 cells to intact aortic
endothelium from fat-fed rabbits. Intact aortic segments from control and
cholesterol-fed New Zealand white rabbits were preincubated with con-
trol IgM  OZ42 or LM151 (50  g/ml) for 20 min. Fluorescent-labeled
WEHI78/24 cells were added, allowed to bind for 30 min at RT under
constant rotation, and then washed extensively to remove nonadherent
cells. The number of adherent cells in 15 fields (totaling 1.4 cm2) was de-
termined on at least five independent segments from at least four rabbits
for each condition.2075 McEvoy et al.
to stain mouse leukocytes by FACS analysis. Fifth, the ex-
pression and superinduction of VMAP-1 on bEnd3 cells con-
trasts with the patterns of endothelial regulation of VCAM-1,
VCAM-GPI, ICAM-2, MAdCAM-1, the IG9 antigen, P-,
and E-selectin. VMAP-1 is constitutively expressed by bEnd3
cells and can be superinduced by TNF-  and LPS while
VCAM-1 (9), VCAM-GPI (29), MAdCAM-1 (33), and
E-selectin (9, and Hubbe, M. and L.M. McEvoy, unpub-
lished observation) are only expressed after stimulation by
LPS or cytokines. ICAM-2 is constitutively expressed and
is not upregulated by TNF-  stimulation of mouse endo-
thelioma cell lines (31) including bEnd3 cells (McEvoy,
L.M., unpublished observation). Furthermore, induced ex-
pression of E-selectin in mouse endotheliomas returns to
baseline levels 24 h after stimulation (9), unlike the sus-
tained expression of VMAP-1. In contrast to the sustained
superinduced expression of VMAP-1 after cytokine stimu-
lation, P-selectin is rapidly upregulated and subsequently
lost after cytokine stimulation by other mouse endothe-
lioma cells (9). It is unlikely that anti–VMAP-1 mAbs rec-
ognize the mouse homologue of the IG9 antigen (27) since
VMAP-1 is constitutively expressed by cultured RAEC,
whereas IG9 antigen is not, and the kinetics of induction of
the IG9 antigen (27) are distinct from those of VMAP-1.
Sixth, blocking mAbs to  4, the monocyte receptor for
VCAM-1 and CS-1–containing fibronectin, and  2 inte-
grins, the monocyte receptors for ICAM-1 and -2, have no
inhibiting effect on induced WEHI78/24 binding. Seventh,
anti–VMAP-1 mAbs LM151, LM141, and LM92 fail to
stain mouse ICAM-1, VCAM-1, or MAdCAM-1 trans-
fected Chinese hamster ovary and CD31 transfected COS
cells (McEvoy, L.M., and E.C. Butcher, personal observa-
tion). Finally, although several vascular adhesion receptors
are widely expressed by other cell types (especially ICAM-1
and VCAM-1), as is VMAP-1, here also the pattern of cell
type–specific staining with anti–VMAP-1 mAbs are distinct
as assessed immunohistologically. Together, these consider-
ations indicate that VMAP-1 represents a novel element in-
volved in monocyte vascular adhesion.
The fortuitous cross-reactivity of LM151 with rabbit
VMAP-1 allowed evaluation of the role of VMAP-1 in
monocyte binding to endothelium in several well-charac-
terized models of atherosclerosis. As described above, Kim
et al. have demonstrated that treatment of rabbit (and human)
aortic endothelial cells with MM-LDL results in a mono-
cyte-selective increase in adhesiveness without upregulation
or involvement of VCAM-1, E-selectin, or ICAM-1 (8).
Anti–VMAP-1 mAb LM151 abrogates binding of human
monocytes to MM-LDL–stimulated RAEC. Furthermore,
the enhanced binding of WEHI78/24 cells to the intact aor-
tic endothelium after cholesterol feeding of New Zealand
white rabbits is also abrogated by LM151 pretreatment of
the endothelium in ex vivo binding assays. These data indi-
cate that VMAP-1 plays a role in the monocyte-selective
adhesiveness stimulated by MM-LDL or cholesterol feed-
ing, suggesting that VMAP-1 may play a role in enhanced
monocyte recruitment in the rabbit models studied here.
Additional studies are required to identify a potential
VMAP-1 homologue in humans.
Monocytes and monocytoid cells bind poorly in our as-
says to unstimulated endothelial cells in vitro and to normal
aortic endothelium ex vivo. Significant binding is only ob-
served after “activation” of the endothelium by LPS, cy-
tokine, or MM-LDL stimulation in vitro, or by fat feeding
in vivo. Superinduction of VMAP-1 by these studies may
contribute to the upregulation of monocyte binding; how-
ever, significant constitutive expression of VMAP-1 by en-
dothelium suggests that VMAP-1 is not likely the sole de-
terminant of monocyte binding, but instead must function
in conjunction with other adhesion and/or signaling mole-
cules in regulation of monocyte interactions. This concept
is consistent with our current model of leukocyte–endo-
thelial interaction as a multistep process in which involve-
ment of several adhesion and activating molecules in se-
quence is required for firm adhesion to endothelium and
successful recruitment from the blood. In this context, it is
relevant that stimulation of endothelium can induce ex-
pression of elements that can influence monocyte activa-
tion, adhesion, and/or diapedesis. For example, MM-LDL
has been shown to induce expression of monocyte chemo-
attractant protein 1 (34), macrophage CSF (35), tissue fac-
tor (36), and a GRO homologue in RAEC (37), as well as
a 105-kD adhesion protein for monocytes recognized by
mAb IG9 (27). Many monocyte chemoattractants (includ-
ing macrophage CSF, monocyte chemoattractant protein 1
[2, 38] and platelet activating factor [reviewed in reference
39]) are expressed or displayed by binding to extracellular
matrix molecules in atherosclerotic lesions. Thus, through
regulated constitutive or induced expression of adhesion
molecules and accumulation and display of chemotactic or
activating factors derived from the endothelium or other
local cells (including smooth muscle cells and previously
accumulated monocytes/macrophages), the endothelium
over a lesion may become decorated by a combination of
adhesion, activation, and chemotactic molecules that can
act in concert to recruit monocytes. Our results suggest
that a monocyte-selective role of VMAP-1, in combination
with other adhesion pathways and chemotactic factors, may
contribute to the inducible multistep cascade controlling
monocyte-selective adhesion and extravasation in athero-
genesis.
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